Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03967600 · ClinicalTrials.gov registry record
Clinical and Biological Characteristics of Hidradenitis Suppurativa
A clinical trial of Hidradenitis Suppurativa, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03967600 is a study of Hidradenitis Suppurativa that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 1,000 participants, above the 579-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03967600, a study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.
Conditions Studied
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-07-15 |
| Est. Completion | 2026-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03967600
The ClinicalTrials.gov registry entry for NCT03967600 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 579-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (73% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 0 interventions.
NCT03967600 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03967600 about?
NCT03967600 is a clinical study titled "Clinical and Biological Characteristics of Hidradenitis Suppurativa". Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characte...
What is the current status of trial NCT03967600?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2016-07-15. Estimated completion is 2026-07-15.
What conditions does trial NCT03967600 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
Who is sponsoring clinical trial NCT03967600?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03967600 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.